A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®

Phase 3 Recruiting 278 enrolled Qilu Pharmaceutical Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a multicenter, randomized, double-blind comparative study to valuating the efficacy and safety of QL1206 and Prolia® in postmenopausal women with osteoporosis at high risk of fracture.

Timeline

Start: 2025-06-27
Primary completion: 2027-01
Completion: 2027-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Denosumab	Monoclonal antibody	60 mg	Subcutaneous

A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®

Summary

Timeline

Drugs

Indications